BridgeMD
New treatment option for Pancreatectomy
Official title Hybrid Closed-Loop Insulin Delivery After Pancreatectomy
ClinicalTrials.gov ID: NCT07430293
What this study is testing
- What it's testing
- Individuals with diabetes secondary to pancreatectomy experience impaired quality of life, partly due to the challenges of managing highly variable blood glucose levels. Hybrid closed-loop (HCL) automated insulin delivery (AID) systems, widely evaluated in type 1 diabetes, may improve both metabolic outcomes and quality of life in this population.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Age from 18 years
- History of total or partial pancreatectomy with random C-peptide \< 0.3 ng/mL and concomitant blood glucose between 120 and 225 mg/dL (no minimum...
- Total daily insulin dose between 6 units and 250 units
- Be affiliated to a French social security scheme
- Individual able and willing to provide written informed consent
You likely can't join if
- Presence of diabetic retinopathy at or beyond severe non-proliferative diabetic retinopathy, not stabilized by ophthalmologic treatment
- Usual diabetes treatment with an insulin pump coupled with continuous glucose monitoring with a "suspend before hypoglycemia" system
- Pregnant woman or planned pregnancy within the next 6 months
- Planned chemotherapy within the next 6 months
- Enteral or parenteral nutrition
- Estimated life expectancy less than 12 months
See the full eligibility criteria
- Age from 18 years
- History of total or partial pancreatectomy with random C-peptide \< 0.3 ng/mL and concomitant blood glucose between 120 and 225 mg/dL (no minimum delay required since surgery)
- Total daily insulin dose between 6 units and 250 units
- Be affiliated to a French social security scheme
- Individual able and willing to provide written informed consent
- Presence of diabetic retinopathy at or beyond severe non-proliferative diabetic retinopathy, not stabilized by ophthalmologic treatment
- Usual diabetes treatment with an insulin pump coupled with continuous glucose monitoring with a "suspend before hypoglycemia" system
- Pregnant woman or planned pregnancy within the next 6 months
- Planned chemotherapy within the next 6 months
- Enteral or parenteral nutrition
- Estimated life expectancy less than 12 months
- Cognitive or psychiatric disorders compromising the individual's autonomy to manage automated insulin delivery
- Person taking part in another research study or with an exclusion period still in progress
- Individual under legal guardianship or curatorship
- Any contraindication mentioned in the instructions for use of the MiniMed 780 - Simplera
- Imprisoned or otherwise deprived of liberty
The study team makes the final eligibility decision.
Where it's taking place
- Corbeil-Essonnes, France, France
- Paris, France, France
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Corbeil-Essonnes, France, France; Paris, France, France. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.